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www.sciencedirect.comThe use of statins is essential for the treatment of hyperlipidemia as well as
for the primary and secondary prevention of coronary artery disease and
strokes. Statins decrease low-density lipoprotein (LDL) cholesterol levels
by inhibiting 3-hydroxy-3-methyl-glutaryl-CoA HMG-CoA reductase
(HMGCR). HMGCR in turn catalyses the conversion of HMG-CoA into
mevalonic acid, an important intermediate metabolite in hepatic cholesterol
biosynthesis. Statins exert pleiotropic effects independent of their choles-
terol-lowering activity, which are in part mediated by mevalonic acid, a
precursor of the isoprenoid intermediates farnesyl and geranyl-geranyl
pyrophosphate [1]. These compounds participate in the post-translational
modification of intracellular G-proteins, such as Rho, Rac, and Ras. In turn, it
is well-known that G-proteins drive signalling pathways that are widely
involved in carcinogenesis [2], and their inhibition by statins has been
proven to efficiently impair the growth of several tumours [3]. Furthermore,
statins inhibit cellular matrix metalloproteinases and nuclear factor-kB (NF-
kB) transcription factors that are, additionally, often deregulated in cancer. A
large body of studies exists that support the efficacy of statins against several
cancer types [3]. For this reason, these compounds has been proposed as
adjuvant options in cancer therapies and in cancer prevention. Currently,
recommendations and guidelines on statin use in malignancies do not exist;
in addition, to date, results from randomised controlled trials are incon-
clusive regarding the question of whether cancer treatment may benefit
from statins.
Very recently, a number of studies, have found that atorvastatin is a powerful
stimulus for endoglin production [4–6]. For example, atorvastatin was shown
to stimulate expression of endoglin in human umbilical vein endothelial
cells (HUVEC), at both transcriptional and protein levels [4]. Endoglin
mRNA levels meanwhile, were found to be increased in the endothelium of
subjects that were statin recipients, in comparison with subjects that were
not statin recipients [4]. In addition, high levels of endoglin were measured
in the blood of subjects with familial hypercholesterolemia that were under
chronic statin treatment [5]. Lastly, Nachtigal et al. also found that statin
treatment significantly induced endoglin expression in the aortic endo-
thelium in atherosclerosis models [6].
Endoglin, or CD105 as it was designated at the Fifth International Work-
shop on Human Leukocyte Differentiation Antigens, is an accessory re-
ceptor of the Transforming Growth Factor (TGF)-b family of proteins,
which includes TGF-b, bone morphogenetic proteins (BMPs), and activins.f the authors who, as experts, reflect on the direction of future research in their field.
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receptors (TbRI and TbRII), and modulates TGF-b
signalling. Stimuli that increase endoglin expression
promote the BMP signalling pathway, which is active
during embryonic development and is reactivated during
adult vasculogenesis. CD105 expression in vascular endo-
thelial cells of de novo blood vessels is therefore con-
sidered to be potentially useful in the detection of cancer
patients with high risks of disease recurrence and metas-
tasis formation [7]. In addition, CD105 expression was
found to be of particular significance in the evaluation of
neoangiogenesis and prediction of prognosis in brain
tumours [8]. Endoglin is predominantly expressed in
proliferating endothelial cells that participate in tumour
angiogenesis, with weak or no expression in the vascular
endothelium of normal tissues; for this reason CD105 is
considered as a suitable vascular target for antiangioge-
netic cancer therapy.
Angiogenesis is a powerful element that drives tumour
progression. Blockage of angiogenesis maintains tumours
in a harmless state and constrains the outgrowth of
metastases. Inability to initiate angiogenesis in dissemi-
nated tumour cells is considered as one of the main causes
of tumour dormancy. Selective targeting of proliferating
endothelial cells within tumour-associated blood vessels
represents one of the most pursued approaches to limit
tumour progression, with molecules that are overex-
pressed in actively proliferating endothelial cells being
attractive targets for antiangiogenetic strategies. Among
these targets, endoglin is considered to be of prime
importance, due to the central role this molecule exerts
in tumour angiogenesis.
Currently, there are no studies directly linking statins
with endoglin production and tumour progression. In
addition, an in-depth characterisation of the mechanism
by which statins induce CD105 is still lacking. However,
it is worth noting that several studies show conversely that
statins can promote cancer [9], suggesting that pro-
tumoural mechanisms might be, in addition, activated
by these drugs.
The undoubtedly striking and specific inhibitory actions
on tumourigenic pathways exerted by statins are consist-
ent with a protective action for these agents in cancer
prevention [10]. The efficient pro-apoptotic activities
exerted by statins, at doses much higher than those used
to lower cholesterol, suggest that these compounds couldCurrent Opinion in Pharmacology 2013, 13:309–310have an effective role, if used in concert with chemother-
apy, in cancer treatment. However, the possibility cannot
be excluded that statins may promote progression of pre-
existing, asymptomatic and even dormant tumours
because of their capacity to stimulate CD105. These
observations are consistent with a dual role for statins
in cancer prevention and progression. The role of statins
in cancer represents an open question that requires urgent
addressing and careful investigation, in both experimen-
tal and pre-clinical settings. Besides prospective studies,
clinical trials may be required to define unambiguously
the ultimate biological effects of statins in cancer inter-
vention and thus the patient population that could benefit
most from this treatment. Finally, it is worth emphasising
that millions of healthy people, including both children
and adults, are currently taking statin drugs.References
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